TTD | Drug: D06BJG

Drug General Information
Drug ID	D06BJG
Former ID	DIB019467
Drug Name	compound 38
Drug Type	Small molecular drug
Indication	Discovery agent		Investigative	[532836]
Formula	C31H26F3N7O4
InChI	InChI=1S/C31H26F3N7O4/c1-3-26(42)35-17-27(43)38-21-8-5-9-22(13-21)41-30-36-15-24(16-37-30)40-29(45)25-14-23(11-10-18(25)2)39-28(44)19-6-4-7-20(12-19)31(32,33)34/h3-16H,1,17H2,2H3,(H,35,42)(H,38,43)(H,39,44)(H,40,45)(H,36,37,41)
InChIKey	SMOPKEHQPPXRSH-UHFFFAOYSA-N
PubChem Compound ID	71556703
PubChem Substance ID	163556749, 240922184, 242042220, 242648958, 249565825
Target and Pathway
Target(s)	tec protein tyrosine kinase	Target Info	Inhibitor	[532836]
	Tyrosine-protein kinase BTK	Target Info	Inhibitor	[532836]
	BLK proto-oncogene, Src family tyrosine kinase	Target Info	Inhibitor	[532836]
	Receptor protein-tyrosine kinase erbB-4	Target Info	Inhibitor	[532836]
	BMX non-receptor tyrosine kinase	Target Info	Inhibitor	[532836]
	TXK tyrosine kinase	Target Info	Inhibitor	[532836]
	mRNA of HER2	Target Info	Inhibitor	[532836]
	Epidermal growth factor receptor	Target Info	Inhibitor	[532836]
KEGG Pathway	NF-kappa B signaling pathway
	Osteoclast differentiation
	Platelet activation
	B cell receptor signaling pathway
	Fc epsilon RI signaling pathway
	Primary immunodeficiencyhsa04012:ErbB signaling pathway
	Calcium signaling pathway
	Endocytosis
	Proteoglycans in cancerhsa04012:ErbB signaling pathway
	HIF-1 signaling pathway
	Focal adhesion
	Adherens junction
	Pathways in cancer
	Proteoglycans in cancer
	MicroRNAs in cancer
	Pancreatic cancer
	Endometrial cancer
	Prostate cancer
	Bladder cancer
	Non-small cell lung cancer
	Central carbon metabolism in cancerhsa04010:MAPK signaling pathway
	ErbB signaling pathway
	Ras signaling pathway
	Rap1 signaling pathway
	Cytokine-cytokine receptor interaction
	FoxO signaling pathway
	PI3K-Akt signaling pathway
	Dorso-ventral axis formation
	Gap junction
	Regulation of actin cytoskeleton
	GnRH signaling pathway
	Estrogen signaling pathway
	Oxytocin signaling pathway
	Epithelial cell signaling in Helicobacter pylori infection
	Hepatitis C
	Glioma
	Melanoma
	Central carbon metabolism in cancer
	Choline metabolism in cancer
NetPath Pathway	TCR Signaling PathwayNetPath_16:IL4 Signaling Pathway
NetPath Pathway	EGFR1 Signaling Pathway
PANTHER Pathway	B cell activationP00004:Alzheimer disease-presenilin pathway
	Cadherin signaling pathway
	EGF receptor signaling pathwayP00012:Cadherin signaling pathway
	EGF receptor signaling pathway
Pathway Interaction Database	Fc-epsilon receptor I signaling in mast cells
	BCR signaling pathway
	FAS (CD95) signaling pathway
	Class I PI3K signaling events
	EPO signaling pathwayerbb4_pathway:ErbB4 signaling events
	ErbB2/ErbB3 signaling events
	ErbB receptor signaling network
	a6b1 and a6b4 Integrin signaling
	Validated targets of C-MYC transcriptional repressionlysophospholipid_pathway:LPA receptor mediated events
	Signaling events mediated by PTP1B
	Arf6 signaling events
	Signaling events mediated by TCPTP
	Thromboxane A2 receptor signaling
	SHP2 signaling
	Regulation of Telomerase
	EGF receptor (ErbB1) signaling pathway
	EGFR-dependent Endothelin signaling events
	Posttranslational regulation of adherens junction stability and dissassembly
	Direct p53 effectors
	ErbB1 downstream signaling
	Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
	E-cadherin signaling in keratinocytes
	Internalization of ErbB1
	Stabilization and expansion of the E-cadherin adherens junction
	Syndecan-3-mediated signaling events
PathWhiz Pathway	Fc Epsilon Receptor I Signaling in Mast CellsPW000168:Phosphatidylinositol Phosphate Metabolism
Reactome	MyD88:Mal cascade initiated on plasma membrane
	Regulation of actin dynamics for phagocytic cup formation
	DAP12 signaling
	FCERI mediated Ca+2 mobilization
	MyD88 deficiency (TLR2/4)
	IRAK4 deficiency (TLR2/4)
	RHO GTPases Activate WASPs and WAVEs
	Antigen activates B Cell Receptor (BCR) leading to generation of second messengersR-HSA-1250196:SHC1 events in ERBB2 signaling
	PLCG1 events in ERBB2 signaling
	PIP3 activates AKT signaling
	GRB2 events in ERBB2 signaling
	PI3K events in ERBB2 signaling
	Constitutive Signaling by Aberrant PI3K in Cancer
	Sema4D induced cell migration and growth-cone collapse
	RAF/MAP kinase cascadeR-HSA-1236382:Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
	SHC1 events in ERBB2 signaling
	GRB2 events in EGFR signaling
	GAB1 signalosome
	SHC1 events in EGFR signaling
	EGFR downregulation
	EGFR Transactivation by Gastrin
	Constitutive Signaling by EGFRvIII
	RAF/MAP kinase cascade
WikiPathways	Kit receptor signaling pathway
	MyD88:Mal cascade initiated on plasma membrane
	Signaling by the B Cell Receptor (BCR)
	DAP12 interactions
	B Cell Receptor Signaling Pathway
	TSLP Signaling Pathway
	Regulation of toll-like receptor signaling pathway
	IL-5 Signaling PathwayWP673:ErbB Signaling Pathway
	EV release from cardiac cells and their functional effectsWP710:DNA Damage Response (only ATM dependent)
	ErbB Signaling Pathway
	EGF/EGFR Signaling Pathway
	Extracellular vesicle-mediated signaling in recipient cells
	Bladder Cancer
	Signaling by ERBB2
	Integrated Pancreatic Cancer Pathway
	Signaling Pathways in Glioblastoma
	Leptin signaling pathway
	miR-targeted genes in muscle cell - TarBase
	Semaphorin interactionsWP673:ErbB Signaling Pathway
	Regulation of Actin Cytoskeleton
	MAPK Signaling Pathway
	Focal Adhesion
	Aryl Hydrocarbon Receptor Pathway
	TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
	Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
	Hair Follicle Development: Induction (Part 1 of 3)
	Signaling by ERBB4
	Gastrin-CREB signalling pathway via PKC and MAPK
	PIP3 activates AKT signaling
	Nanoparticle-mediated activation of receptor signaling
	Aryl Hydrocarbon Receptor
	Spinal Cord Injury
	Gastric cancer network 2
	AGE/RAGE pathway
	Arylhydrocarbon receptor (AhR) signaling pathway
	miR-targeted genes in lymphocytes - TarBase
	miR-targeted genes in epithelium - TarBase
	Integrated Breast Cancer Pathway
	Signaling by EGFR
	L1CAM interactions
References
Ref 532836	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
Ref 532836	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.

Drug Information